Orexigen Therapeutics, Inc. (NASDAQ:OREX)
| CAPS Rating |
|
|---|---|
| Open | $3.08 |
| Previous Close | $3.11 |
| Daily Range | $3.01 - $3.10 |
| 52-Week Range | $1.22 - $3.56 |
| Market Cap | $145.70M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 374,684 |
| Average Daily Volume | 0 |
OREX
VS S&P 500 (SPY)
How do you think OREX will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
OREX Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
OREX News and Commentary
- Diet Pill Scorecard: Vivus, Arena, Orexigen Still Chasing Market Approvals – Minyanville
- Has Arena Pharmaceuticals Become the Perfect Stock? – The Motley Fool
- Don't Believe This Company's Warning – The Motley Fool
- Arena Pharma Files Response to CRL - Analyst Blog – NASDAQ
- This Biotech's Obese To-Do List Is Done – The Motley Fool
- Working Through the Obese To-Do List in 2011 – The Motley Fool
- VIVUS' Obese Pink Elephant – The Motley Fool
- US Stock Futures: HOT STOCKS TO WATCH – SmartMoney
- US Stock Futures: HOT STOCKS TO WATCH – SmartMoney
- Zacks #1 Rank Additions for Thursday - Tale of the Tape – NASDAQ
- Even With a Pill That Works Faster Than Viagra, Vivus Isn't a Buy – Minyanville
- These 2 Biotechs Got Crushed – The Motley Fool
- Aeterna Zentaris Surprises Again – The Motley Fool
- 3 Stocks Shaking the Market – The Motley Fool
- Closer to Approval, Now Can MELA Find Customers? – The Motley Fool
- Obesity-Drug Makers Stop Getting Bullied – The Motley Fool
- Orexigen Revives Obesity Drug After One More Go-Round With FDA – The Motley Fool
- Orexigen Surges on New Hope for Diet Pill – Minyanville
- Arena Pharmaceuticals Shares Popped: What You Need to Know – The Motley Fool
- A Shrinking Obesity Market – The Motley Fool
RSS Headlines
Fool UK
